Sandoz has signed an agreement to acquire ranibizumab biosimilar Cimerli from Coherus BioSciences, according to a press release.
The $170 million cash deal includes a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, and access to proprietary commercial software.
Sandoz said the deal will allow it to build a more robust ophthalmic platform that could support future product launches.
“I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise,”